Gene · 5890
Papers1,861
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
161 to 180 of 1,861
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Sequential genomic analysis using a multisample/multiplatform approach to better define rhabdomyosarcoma progression and relapse. | NPJ Precis Oncol | 2023 | 37730754 | PubTator, text mining | PubMed |
| Performance of a RAD51-based functional HRD test on paraffin-embedded breast cancer tissue. | Breast Cancer Res Treat | 2023 | 37725154 | PubTator, text mining | PubMed |
| Biomarker-Directed Therapy in Black and White Men With Metastatic Castration-Resistant Prostate Cancer. | JAMA Netw Open | 2023 | 37721753 | PubTator, text mining | PubMed |
| A pan-sarcoma landscape of telomeric content shows that alterations in RAD51B and GID4 are associated with higher telomeric content. | NPJ Genom Med | 2023 | 37709802 | PubTator, text mining | PubMed |
| In vivo gene expression profile of Haemophilus influenzae during human pneumonia. | Microbiol Spectr | 2023 | 37707456 | PubTator, text mining | PubMed |
| CRISPR screens in sister chromatid cohesion defective cells reveal PAXIP1-PAGR1 as regulator of chromatin association of cohesin. | Nucleic Acids Res | 2023 | 37702151 | PubTator, text mining | PubMed |
| Extraction Protocol for Parallel Analysis of Proteins and DNA from Ancient Teeth and Dental Calculus. | J Proteome Res | 2023 | 37699853 | PubTator, text mining | PubMed |
| Hot on RAD51C: structure and functions of RAD51C-XRCC3. | Mol Oncol | 2023 | 37681281 | PubTator, text mining | PubMed |
| Ovarian high-grade serous carcinoma with transitional-like (SET) morphology: a homologous recombination-deficient tumor. | Hum Pathol | 2023 | 37673346 | PubTator, text mining | PubMed |
| Biological differences underlying sex and gender disparities in bladder cancer: current synopsis and future directions. | Oncogenesis | 2023 | 37666817 | PubTator, text mining | PubMed |
| Brief Report: Clinical Response, Toxicity, and Resistance Mechanisms to Osimertinib Plus MET Inhibitors in Patients With EGFR-Mutant MET-Amplified NSCLC. | JTO Clin Res Rep | 2023 | 37649681 | PubTator, text mining | PubMed |
| Mapping the Genetic Interaction Network of PARP inhibitor Response. | bioRxiv | 2023 | 37645833 | PubTator, text mining | PubMed |
| The DDUP protein encoded by the DNA damage-induced CTBP1-DT lncRNA confers cisplatin resistance in ovarian cancer. | Cell Death Dis | 2023 | 37633920 | PubTator, text mining | PubMed |
| Human Exome Sequencing and Prospects for Predictive Medicine: Analysis of International Data and Own Experience. | J Pers Med | 2023 | 37623486 | PubTator, text mining | PubMed |
| The Spectrum of Germline Nucleotide Variants in Gastric Cancer Patients in the Kyrgyz Republic. | Curr Issues Mol Biol | 2023 | 37623222 | PubTator, text mining | PubMed |
| Uterine collision tumor (PEComa and endometrioid carcinoma) in a tuberous sclerosis patient: a case report. | Front Oncol | 2023 | 37621679 | PubTator, text mining | PubMed |
| Next generation sequencing reveals a high prevalence of pathogenic mutations in homologous recombination DNA damage repair genes among patients with uterine sarcoma. | Gynecol Oncol | 2023 | 37611378 | PubTator, text mining | PubMed |
| Prevalence and spectrum of cancer predisposition germline mutations in young patients with the common late-onset cancers. | Cancer Med | 2023 | 37610374 | PubTator, text mining | PubMed |
| The dynamic process of covalent and non-covalent PARylation in the maintenance of genome integrity: a focus on PARP inhibitors. | NAR Cancer | 2023 | 37609662 | PubTator, text mining | PubMed |
| Characterization of m6A modifiers and RNA modifications in uterine fibroids. | bioRxiv | 2023 | 37609293 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/5890/papers?page=9